| NCT ID | NCT06521801 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Queen Mary University of London |
| Condition | End Stage Renal Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 60,000 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2030-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60,000 participants in total. It began in 2024-08-01 with a primary completion date of 2030-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality risk progressively increases with worsening CKD. As glomerular filtration rate (GFR) declines the probability of developing coronary artery disease (CAD) increases linearly, and patients with GFR \<60 mL/min/1.73 m2 have 2-3-fold increased CV mortality risk, relative to patients without CKD. Management of CAD is complicated in CKD patients due to the likelihood of comorbid conditions and potential for side effects. Despite their high cardiovascular risk, ACS patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularisation. This observation, referred to as the "treatment risk paradox," has been well described and may be explained by physicians' concerns regarding possible nonrenal side effects as well as renal toxicities. Furthermore, patients with severe CKD have traditionally been under-represented in most large cardiovascular clinical trials. Therefore, recommendations for both medical and revascularisation of CAD have relied heavily on extrapolation of results from the non-CKD population. This data will add to that literature by assessing the characteristics and outcomes of patients with CAD and CKD. It will also identify and characterise predictors of outcomes, improve risk stratification and diagnostic evaluation.
Eligibility Criteria
Informed consent will not be sought for, as patients are automatically included onto a database that we will use for research purposes. No children will be included in this study. Vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the Nephrology team. Inclusion Criteria: 1. Both male and female patients ≥16 years of age will be included 2. All patients will be reviewed by the Nephrology team a the RLH with renal disease. Exclusion Criteria: 1\. Patients \<16 years will not be included in this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06521801 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying End Stage Renal Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06521801 currently recruiting?
Yes, NCT06521801 is actively recruiting participants. Contact the research team at k.s.rathod@qmul.ac.uk for enrollment information.
Where is the NCT06521801 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT06521801 clinical trial?
NCT06521801 is sponsored by Queen Mary University of London. The trial plans to enroll 60,000 participants.